| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/06/2004 | EP1414432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 05/06/2004 | EP1414429A2 Dermatological preparations containing an nsaid |
| 05/06/2004 | EP1414425A1 Amine compounds and inhibiting neurotransmitter reuptake |
| 05/06/2004 | EP1414424A1 Agent for treating the symptoms of dementia disorders containing an additional local anesthetic agent |
| 05/06/2004 | EP1414423A1 Agent for treating depressive disorders containing a local anesthetic agent |
| 05/06/2004 | EP1414421A1 The treatment of lipodystrophy |
| 05/06/2004 | EP1414418A1 Compositions and methods to prevent abuse of opioids |
| 05/06/2004 | EP1414411A1 Pulmonary formulation comprising silicon particles |
| 05/06/2004 | EP1414409A1 Stabilized oral suspension formulation |
| 05/06/2004 | EP1414405A1 Invert emulsion containing dhea |
| 05/06/2004 | EP1353665A4 Treatment of depression |
| 05/06/2004 | EP1226438B1 Composite nanospheres and their conjugates with biomolecules |
| 05/06/2004 | EP1181027B1 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/06/2004 | EP1165138B1 Programmed controlled ovarian stimulation protocol using oral contraceptives |
| 05/06/2004 | EP1137409B1 Compositions and methods for amelioration of human female sexual dysfunction |
| 05/06/2004 | EP1123283B1 Thiazole-derivatives |
| 05/06/2004 | EP1098626B1 Method for regulating hair growth |
| 05/06/2004 | EP1009390A4 Prolonged anesthesia in joints and body spaces |
| 05/06/2004 | EP0980203A4 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 05/06/2004 | EP0918542B1 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 05/06/2004 | EP0831932B1 Novel targeted compositions for diagnostic and therapeutic use |
| 05/06/2004 | DE10248601A1 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/06/2004 | DE10142665B4 C2-Disubstituierte Indan-1-one und ihre Derivate C2-Disubstituted indan-1-one and its derivatives |
| 05/06/2004 | CA2528776A1 Antifungal formulations |
| 05/06/2004 | CA2505597A1 Agent elevating dendritic cell precursor level in blood |
| 05/06/2004 | CA2503536A1 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 05/06/2004 | CA2503391A1 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 05/06/2004 | CA2503054A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2500829A1 Prophylactic treatment methods |
| 05/06/2004 | CA2500090A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | CA2493806A1 Aqueous iron carbohydrate complexes, their production and medicaments containing them |
| 05/05/2004 | CN2614212Y Multi channel microcapsule generating apparatus |
| 05/05/2004 | CN1494592A Nucleic acid expressed in hypothalamus or muscle tissue in obese animals |
| 05/05/2004 | CN1494553A Modified antibodies and method of use |
| 05/05/2004 | CN1494552A Flt 4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 05/05/2004 | CN1494542A 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 05/05/2004 | CN1494539A Antagonists of MCP-1 function and methods of use thereof |
| 05/05/2004 | CN1494435A Preparation for prophylaxis of restenosis |
| 05/05/2004 | CN1494433A Use of CD 23 antagonists for treatment of neoplastic disorders |
| 05/05/2004 | CN1494422A Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for treatment of cognitive disorders |
| 05/05/2004 | CN1494420A Compounds and compositions for delivering active agents |
| 05/05/2004 | CN1493395A Nano-titanium dioxide photocatalyst film, preparation and its application |
| 05/05/2004 | CN1148189C Quinoline carboxamides as TNF inhibitors and as PDC-IV inhibitors |
| 05/05/2004 | CN1148187C Application of tetrandrine its agonist for preparing medicine for treatment of ocular inflammation |
| 05/05/2004 | CN1148186C Clonidine preparation |
| 05/05/2004 | CN1148179C 20-Hete antagonists and agonists |
| 05/04/2004 | US6730778 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 05/04/2004 | US6730707 Method for reducing intraocular pressure using indole derivatives |
| 05/04/2004 | US6730698 Method and compositions for administering taxanes orally to human patients |
| 05/04/2004 | US6730692 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 05/04/2004 | US6730691 Ophthalmic solution for inhibiting visual anomalies experienced by an individual who undergone refractive eye surgery comprising alpha adrenergic blocking agents, one or more anti-irritant agents, and one or more anti-inflammatory |
| 05/04/2004 | US6730674 Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| 05/04/2004 | US6730664 The side-effects of chemotherapy are suppressed or reduced |
| 05/04/2004 | US6730505 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/04/2004 | US6730486 Human βTrCP protein |
| 05/04/2004 | US6730480 Sphingosine kinase enzyme |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730320 Doxycycline administered in three dosages forms of different release profiles, with cmax being reached in < twelve hours |
| 05/04/2004 | US6730319 Pharmaceutical compositions having depressed melting points |
| 05/04/2004 | US6730301 Mediating chemotaxis and activation of monocytes; athero-sclerosis; monocyte chemoattractant protein-1 (mcp-1) |
| 05/04/2004 | US6730299 Kit; simple, practical; bioresorbable, nontoxic wound protection; biocompatible fluid and gas; produces foam |
| 05/04/2004 | US6730016 Cardiac disease treatment and device |
| 05/04/2004 | CA2296178C Human intestinal npt2b |
| 05/04/2004 | CA2240296C Endothelial cell proliferation inhibitor and method of use |
| 04/29/2004 | WO2004036224A2 Screening method |
| 04/29/2004 | WO2004035777A1 Adipocyte differentiation-associated genes and proteins |
| 04/29/2004 | WO2004035090A1 Gastric acid secretion inhibiting composition |
| 04/29/2004 | WO2004035089A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | WO2004035088A1 Therapeutics/diagnostics for brain tumor |
| 04/29/2004 | WO2004035065A1 Hypoglycemic substances containing zinc |
| 04/29/2004 | WO2004035059A1 Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
| 04/29/2004 | WO2004035058A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | WO2004035057A1 Therapeutic treatment |
| 04/29/2004 | WO2004035055A1 Use of dopamine receptor agonists for the treatment of cutaneous tumors, warts, and scars |
| 04/29/2004 | WO2004035051A1 Lisinopril/lercanidipine combination therapy |
| 04/29/2004 | WO2004035045A1 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer |
| 04/29/2004 | WO2004035043A1 Clofarabine and platinum chemotherapy combination |
| 04/29/2004 | WO2004035041A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 04/29/2004 | WO2004035037A2 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | WO2004035036A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 04/29/2004 | WO2004035030A2 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 04/29/2004 | WO2004035004A2 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 04/29/2004 | WO2004034990A2 Methods and compositions for use in treating cancer |
| 04/29/2004 | WO2004034975A2 Sustained release profile modification |
| 04/29/2004 | WO2004034968A2 Combination therapy for controlling appetites |
| 04/29/2004 | WO2004034965A2 Method for treating cancer |
| 04/29/2004 | WO2004016221A3 Sulfonamides as potassium channel blockers |
| 04/29/2004 | WO2004012732A3 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/29/2004 | WO2004007770A3 Method for diagnosis of intestinal-type gastric tumors |
| 04/29/2004 | WO2004003185A3 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/29/2004 | WO2004000016A3 Antimicrobial compositions, products and methods employing same |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003086267B1 Multi-phase, multi-compartment capsular system |
| 04/29/2004 | WO2003075840A3 Human antibodies specific to kdr and uses thereof |
| 04/29/2004 | WO2003057134A3 Specific binding agents of human angiopoietin-2 |
| 04/29/2004 | WO2003055500A8 Pharmaceutical compositions for the treatment or prevention of osteoporosis |
| 04/29/2004 | WO2003042399A9 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
| 04/29/2004 | WO2003015612A9 Materials and methods to promote repair of nerve tissue |